Standout Papers

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Gui... 2007 2026 2013 2019 17.6k
  1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)
    Erik von Elm, Douglas G. Altman et al. PLoS Medicine
  2. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)
    Erik von Elm, Douglas G. Altman et al. Annals of Internal Medicine
  3. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2007)
    Erik von Elm, Douglas G. Altman et al. The Lancet
  4. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2008)
    Erik von Elm, Douglas G. Altman et al. Journal of Clinical Epidemiology
  5. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies (2014)
    Erik von Elm, Douglas G. Altman et al. International Journal of Surgery
  6. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007)
    Jan P. Vandenbroucke, Erik von Elm et al. PLoS Medicine
  7. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies (2007)
    Erik von Elm, Douglas G. Altman et al. BMJ
  8. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016)
    Steven P. Marso, Gilbert H. Daniels et al. New England Journal of Medicine
  9. Clinical Trials: A Practical Approach. (1984)
    Ira Hill, Stuart Pocock Biometrics
  10. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies (2007)
    Erik von Elm, Douglas G. Altman et al. Preventive Medicine
  11. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms (2010)
    Faı̈ez Zannad, John J.V. McMurray et al. New England Journal of Medicine
  12. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (2007)
    Jan P. Vandenbroucke, Erik von Elm et al. Epidemiology
  13. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration (2014)
    Jan P. Vandenbroucke, Erik von Elm et al. International Journal of Surgery
  14. Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial (1975)
    Stuart Pocock, Richard Simon Biometrics
  15. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency (2009)
    Stefan D. Anker, Josep Comín Colet et al. New England Journal of Medicine
  16. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (2007)
    Erik von Elm, Douglas G. Altman et al. Epidemiology
  17. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation (2016)
    Karl-Heinz Kuck, Josép Brugada et al. New England Journal of Medicine
  18. Reporting of Noninferiority and Equivalence Randomized Trials (2012)
    Gilda Piaggio, Diana R Elbourne et al. JAMA
  19. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting (1998)
    Martin B. Leon, Donald S. Baim et al. New England Journal of Medicine
  20. Bivalirudin during Primary PCI in Acute Myocardial Infarction (2008)
    Gregg W. Stone, Bernhard Witzenbichler et al. New England Journal of Medicine
  21. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents (2007)
    Gregg W. Stone, Jeffrey W. Moses et al. New England Journal of Medicine
  22. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies* (2007)
    Erik von Elm, Douglas G. Altman et al. Bulletin of the World Health Organization
  23. Group sequential methods in the design and analysis of clinical trials (1977)
    Stuart Pocock Biometrika
  24. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009)
    Philip Home, Stuart Pocock et al. The Lancet
  25. A Factorial Trial of Six Interventions for the Prevention of Postoperative Nausea and Vomiting (2004)
    Christian C. Apfel, K. Korttila et al. New England Journal of Medicine
  26. Reporting of Noninferiority and Equivalence Randomized Trials (2006)
    Gilda Piaggio, Diana R Elbourne et al. JAMA
  27. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies (2012)
    Stuart Pocock, Cono Ariti et al. European Heart Journal
  28. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020)
    Faı̈ez Zannad, João Pedro Ferreira et al. The Lancet
  29. Subgroup analysis and other (mis)uses of baseline data in clinical trials (2000)
    Susan F. Assmann, Stuart Pocock et al. The Lancet
  30. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials (2000)
    Jan A. Staessen, Jerzy Gąsowski et al. The Lancet
  31. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems (2002)
    Stuart Pocock, Linda Kasten et al. Statistics in Medicine
  32. Predictors of mortality and morbidity in patients with chronic heart failure (2005)
    Stuart Pocock, Duolao Wang et al. European Heart Journal
  33. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure (2007)
    G. Michael Felker, Larry A. Allen et al. Journal of the American College of Cardiology
  34. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006)
    Hans L. Hillege, Dorothea Nitsch et al. Circulation
  35. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure (2007)
    Alexandre Mebazaa, Markku S. Nieminen et al. JAMA
  36. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005)
    Scott D. Solomon, Nagesh S. Anavekar et al. Circulation
  37. Strategy for intention to treat analysis in randomised trials with missing outcome data (2011)
    Ian R. White, Nicholas J. Horton et al. BMJ
  38. Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis (2007)
    Philip Home, Stuart Pocock et al. New England Journal of Medicine
  39. Statistical guidelines for contributors to medical journals. (1983)
    David Altman, S M Gore et al. BMJ
  40. Comparison of Propensity Score Methods and Covariate Adjustment (2017)
    Markus C. Elze, John Gregson et al. Journal of the American College of Cardiology
  41. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. (1981)
    A. G. Shaper, Stuart Pocock et al. BMJ
  42. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes (2010)
    Roxana Mehran, Stuart Pocock et al. Journal of the American College of Cardiology
  43. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials (2015)
    Joanna Dobson, Richard J. Whitley et al. The Lancet
  44. BMI and risk of dementia in two million people over two decades: a retrospective cohort study (2015)
    Nawab Qizilbash, John Gregson et al. The Lancet Diabetes & Endocrinology
  45. Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults (2015)
    Usman Baber, Roxana Mehran et al. Journal of the American College of Cardiology
  46. Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient data Meta-Analysis (2017)
    Stefan D. Anker, Bridget‐Anne Kirwan et al. European Journal of Heart Failure
  47. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020)
    Milton Packer, Stefan D. Anker et al. Circulation
  48. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review (2017)
    Kamlesh Khunti, Marília Brito Gomes et al. Diabetes Obesity and Metabolism
  49. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020)
    Stefan D. Anker, Javed Butler et al. Circulation
  50. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial (2021)
    Milton Packer, Javed Butler et al. Circulation
  51. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention (2020)
    Mahesh V. Madhavan, Ajay J. Kirtane et al. Journal of the American College of Cardiology
  52. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial (2022)
    Felix Mahfoud, David E. Kandzari et al. The Lancet
  53. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (2021)
    Javed Butler, Milton Packer et al. European Heart Journal

Immediate Impact

1 from Science/Nature 96 standout
Sub-graph 1 of 21

Citing Papers

Empagliflozin in Patients with Chronic Kidney Disease
2022 Standout
The changing landscape of atherosclerosis
2021 StandoutNature

Works of Stuart Pocock being referenced

Effects of Icosapent Ethyl on Total Ischemic Events
2019
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Stuart Pocock 34883 31770 15196 16294 569 137.2k
Julian P. T. Higgins 17209 31545 10156 21573 446 178.4k
John P. A. Ioannidis 14962 25317 6614 17450 1.1k 180.8k
Ralph B. D’Agostino 57880 28135 31742 25092 1.4k 169.3k
Matthias Egger 18123 35836 9090 31896 751 204.3k
Peter C Gøtzsche 19501 39970 8492 25014 276 196.6k
Andrew S. Levey 30240 17388 13235 15029 503 121.9k
Jan P. Vandenbroucke 12836 21047 4927 15026 439 107.2k
Peter W.F. Wilson 34252 30320 29024 14028 632 107.0k
Gordon Guyatt 19231 32454 7016 22197 1.3k 166.8k
Josef Coresh 29995 15647 16406 13979 936 112.1k

All Works

Loading papers...

Rankless by CCL
2026